Pharvaris (NASDAQ:PHVS - Get Free Report) will likely be announcing its Q1 2025 earnings results before the market opens on Wednesday, May 14th. Analysts expect the company to announce earnings of ($0.80) per share for the quarter.
Pharvaris (NASDAQ:PHVS - Get Free Report) last posted its quarterly earnings data on Monday, April 7th. The company reported ($0.68) earnings per share for the quarter, topping the consensus estimate of ($0.74) by $0.06. On average, analysts expect Pharvaris to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.
Pharvaris Stock Down 1.2%
PHVS traded down $0.21 during trading on Monday, reaching $16.78. The stock had a trading volume of 5,581 shares, compared to its average volume of 73,647. Pharvaris has a 1-year low of $11.51 and a 1-year high of $25.50. The firm has a market capitalization of $877.43 million, a price-to-earnings ratio of -5.99 and a beta of -2.85. The stock has a 50 day moving average of $15.27 and a two-hundred day moving average of $17.84.
Wall Street Analyst Weigh In
Several analysts have issued reports on the company. Cantor Fitzgerald began coverage on Pharvaris in a report on Tuesday, April 29th. They set an "overweight" rating and a $28.00 price objective on the stock. JMP Securities upped their target price on Pharvaris from $46.00 to $55.00 and gave the company a "market outperform" rating in a report on Friday, January 31st.
Check Out Our Latest Research Report on Pharvaris
About Pharvaris
(
Get Free Report)
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.
Featured Articles
Before you consider Pharvaris, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharvaris wasn't on the list.
While Pharvaris currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
